Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US FDA has given its consent to Takeda Pharmaceuticals to rename heartburn drug dexlansoprazole from Kapidex to Dexilant to avoid confusion with other medications Casodex and Kadian, reported PMPNews.
Subscribe to our email newsletter
Takeda Pharma North America will start marketing the drug under the new name in late April 2010.
After Kapidex was approved in January 2009, there have been reports of discrepancies in dispensing because of mix-up with the drugs Casodex (bicalutamide) and Kadian (morphine sulfate), which vary in purpose from Kapidex and from each other, according to FDA.
FDA said: “Kapidex is a proton pump inhibitor used to treat heartburn and other conditions by reducing the amount of acid produced in the stomach. Casodex, marketed by AstraZeneca, is used to treat men with advanced prostate cancer. Kadian, distributed by Actavis Kadian LLC, is an opioid analgesic used to treat pain.”
Janet Woodcock, director of Center for Drug Evaluation and Research at FDA, said: “FDA is pleased to have worked with Takeda to take swift and responsible steps to change the name of this product in the interest of patient safety.”